ClinicalTrials.gg
CompletedNCT00170573Updated Dec 16, 2024Results posted

Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

A Phase 2 interventional study of Caelyx in Ovarian Cancer, sponsored by North Eastern German Society of Gynaecological Oncology. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-16.

Sponsored by North Eastern German Society of Gynaecological Oncology · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
77
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies testing liposomal doxorubicin in Ovarian Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. liposomal doxorubicin · Ovarian Neoplasms.

Enrollment
15th of 42
77 · median 53
Started
2001
the only one that year
Phase 2
14 of 42
none open now
Registered
2nd of 42
by date

Among the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms, this one is the 15th largest by enrollment, is the only one that started in 2001, is one of 14 in phase 2, and was the 2nd registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →

About liposomal doxorubicin

liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies testing liposomal doxorubicin in Ovarian Neoplasms as a file.
02

Study summary

Effect of biweekly schedule of PLD on dose-limiting toxicity of PPE and patient's quality of life

Read the detailed description

Pegylated liposomal doxorubicin (PLD) formulation has been approved for the treatment of recurrent ovarian cancer (ROC). Toxic skin reactions e.g. palmar-plantar erythrodysesthesia (PPE) were reported as being the dose-limiting toxicity and have an impact on patients' quality of life (QoL). The primary aim of this study was to optimise the toxicity profile by choosing a biweekly schedule of PLD Furthermore, QoL was investigated. Secondary objective of this study was to evaluate the response rates of this new regimen.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

Keywords

  • Pegylated liposomal doxorubicin
  • PPE
  • Ovarian Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 18 years of age
  • recurrent ovarian, peritoneal, or tubal cancer and prior treatment with platinum- and paclitaxel were eligible to this trial.
  • (ECOG) performance status less than 3.
  • renal function (serum creatinine 1.25 times the , greater than 60 ml/min)
  • liver function (/ ALT three times the upper limit of normal, concentrations 1.25 the upper limit of normal)
  • bone marrow function ( greater than 1.5 x 109/l, and a count greater than 100 x 109/l).

Exclusion criteria

Exclusion Criteria:

  • patients with more than 4 chemotherapies in medical history
  • severe cardiac disease
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    Caelyx

    40 mg/m² biweekly

    Drug: Caelyx

Interventions

06

What researchers measure

Primary outcomes

  1. Occurrence of Palmar-plantar Erythrodysesthesia (PPE)

    The outcome will be measured by number of participants with reported skin toxicity PPE of CTC (Common Toxicity Criteria)-Grade I / II / III / IV. Grade I - Dysesthesia/paraesthesia tingling of hands and feet; Grade II - Discomfort in holding objects and upon walking, painless swelling and erythema; Grade III - painful erythema and swelling of palms and soles, periungual erythema and swelling; Grade IV - Desquamation, ulceration, blistering, severe pain

    Time frame: through study completion, an average of 18 months

Secondary outcomes

  1. Overall Survival

    Overall survival estimated by the Kaplan-Meier method

    Time frame: for up to 3 years

07

Results

Posted Dec 16, 2024

Participant flow

recruitment period: September 2001 - February 2004

Participant flow — Overall Study
MilestoneCaelyx
Started77
Completed64
Not completed13
Withdrew: Violation of inclusion criteria13

Outcome measures

PrimaryOccurrence of Palmar-plantar Erythrodysesthesia (PPE)

The outcome will be measured by number of participants with reported skin toxicity PPE of CTC (Common Toxicity Criteria)-Grade I / II / III / IV. Grade I - Dysesthesia/paraesthesia tingling of hands and feet; Grade II - Discomfort in holding objects and upon walking, painless swelling and erythema; Grade III - painful erythema and swelling of palms and soles, periungual erythema and swelling; Grade IV - Desquamation, ulceration, blistering, severe pain

Time frame:
through study completion, an average of 18 months
Reported as:
Count of participants · Participants
Occurrence of Palmar-plantar Erythrodysesthesia (PPE)
ParticipantsCaelyx
CTC-Grade I18
CTC-Grade II9
CTC-Grade III3
CTC-Grade IV0
no PPE34
SecondaryOverall Survival

Overall survival estimated by the Kaplan-Meier method

Time frame:
for up to 3 years
Reported as:
Median · months
Overall Survival
monthsCaelyx
Overall Survival18.2 (1.4 to 34.0)

Adverse events

Collected over through study completion, an average of 18 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Caelyx—4/64 (6.3%)60/64 (93.8%)
Most frequent serious events
Most frequent serious events
EventCaelyx
AnemiaBlood and lymphatic system disorders3/64
ThrombopeniaBlood and lymphatic system disorders1/64
Most frequent other events
Most frequent other events
EventCaelyx
PPESkin and subcutaneous tissue disorders30/64
LeucopeniaBlood and lymphatic system disorders26/64
ThrombopeniaBlood and lymphatic system disorders4/64

Baseline characteristics

Age, Continuous
Age, Continuous(years)Caelyx
Median59 (38 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Caelyx
Female64
Male0
Region of Enrollment
Region of Enrollment(participants)Caelyx
Germany64
Classification of tumour (according to FIGO ovarian cancer staging)
Classification of tumour (according to FIGO ovarian cancer staging)(participants)Caelyx
stage IA2
stage IB0
stage IC1
stage IIA8
stage IIB2
stage IIC4
stage IIIA2
stage IIIB3
stage IIIC34
stage IV7
unknown1
Histological grade
Histological grade(participants)Caelyx
grade 18
grade 220
grade 328
grade 40
unknown8
ECOG performance status
ECOG performance status(participants)Caelyx
020
134
210
30
40
50
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2001, a primary completion of Apr 2009 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2024, 15 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 15, 2005
Start
Sep 2001
Primary completionActual
Apr 2009
CompletionActual
Aug 2010
Results first posted
Dec 16, 2024
Last update
Dec 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00170573
Lead sponsor
North Eastern German Society of Gynaecological Oncology
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Sep 2001
Primary completion
Apr 2009
Completion
Aug 2010
Results posted
Dec 16, 2024
Last update
Dec 16, 2024

Study contacts

Jalid Sehouli
principal investigator · Charite University, Berlin, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal doxorubicin

Start the discussion